Search

Your search keyword '"Wijsenbeek, Marlies S."' showing total 454 results
Start Over Author "Wijsenbeek, Marlies S."
454 results on '"Wijsenbeek, Marlies S."'

12. Home monitoring in interstitial lung diseases

Author

Wijsenbeek, Marlies S, Moor, Catharina C, Johannson, Kerri A, Jackson, Peter D, Khor, Yet H, Kondoh, Yasuhiro, Rajan, Sujeet K, Tabaj, Gabriela C, Varela, Brenda E, van der Wal, Pieter, van Zyl-Smit, Richard N, Kreuter, Michael, and Maher, Toby M

Published
2023
Full Text
View/download PDF

16. Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis

Author

Marinescu, Daniel-Costin, Raghu, Ganesh, Remy-Jardin, Martine, Travis, William D., Adegunsoye, Ayodeji, Beasley, Mary Beth, Chung, Jonathan H., Churg, Andrew, Cottin, Vincent, Egashira, Ryoko, Fernández Pérez, Evans R., Inoue, Yoshikazu, Johannson, Kerri A., Kazerooni, Ella A., Khor, Yet H., Lynch, David A., Müller, Nestor L., Myers, Jeffrey L., Nicholson, Andrew G., Rajan, Sujeet, Saito-Koyama, Ryoko, Troy, Lauren, Walsh, Simon L.F., Wells, Athol U., Wijsenbeek, Marlies S., Wright, Joanne L., and Ryerson, Christopher J.

Published
2022
Full Text
View/download PDF

19. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey

Author

Morisset, Julie, Johannson, Kerri A, Jones, Kirk D, Wolters, Paul J, Collard, Harold R, Walsh, Simon LF, Ley, Brett, Antoniou, Katerina M, Assayag, Deborah, Behr, Juergen, Bonella, Francesco, Brown, Kevin K, Collins, Bridget F, Cormier, Yvon, Corte, Tamera J, Costabel, Ulrich, Danoff, Sonye K, de Boer, Kaïssa, Fernandez Perez, Evans R, Flaherty, Kevin R, Goh, Nicole SL, Glaspole, Ian, Jones, Mark G, Kondoh, Yasuhiro, Kreuter, Michael, Lacasse, Yves, Lancaster, Lisa H, Lederer, David J, Lee, Joyce S, Maher, Toby M, Martinez, Fernando J, Meyer, Keith C, Mooney, Joshua J, Gall, Xavier Muñoz, Noble, Paul W, Noth, Imre, Oldham, Justin M, Alberto de Castro Pereira, Carlos, Poletti, Venerino, Selman, Moises, Spagnolo, Paolo, Renzoni, Elisabetta, Richeldi, Luca, Ryerson, Christopher J, Ryu, Jay H, Salisbury, Margaret L, Strek, Mary E, Tomassetti, Sara, Valeyre, Dominique, Vancheri, Carlo, Wijsenbeek, Marlies S, and Wuyts, Wim

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Alveolitis, Extrinsic Allergic, Chronic Disease, Consensus, Delphi Technique, Female, Humans, Internationality, Male, Surveys and Questionnaires, hypersensitivity pneumonitis, interstitial lung disease, diagnosis, Delphi, HP Delphi Collaborators, Diagnosis, Hypersensitivity pneumonitis, Interstitial Lung Disease, Medical and Health Sciences, Respiratory System, Cardiovascular medicine and haematology, Clinical sciences
Abstract

RationaleCurrent diagnosis of chronic hypersensitivity pneumonitis (cHP) involves considering a combination of clinical, radiological, and pathological information in multidisciplinary team discussions. However, this approach is highly variable with poor agreement between centers.ObjectivesWe aimed to identify diagnostic criteria for cHP that reach consensus among international experts.MethodsA 3-round modified Delphi survey was conducted between April and August 2017. Forty-five experts in interstitial lung disease from 14 countries participated in the online survey. Diagnostic items included in round 1 were generated using expert interviews and literature review. During rounds 1 and 2, experts rated the importance of each diagnostic item on a 5-point Likert scale. The a priori threshold of consensus was ≥ 75% of experts rating a diagnostic item as very important or important. In the third round, experts graded the items that met consensus as important and provided their level of diagnostic confidence for a series of clinical scenarios.Measurements and main resultsConsensus was achieved on 18 of the 40 diagnostic items. Among these, experts gave the highest level of importance to the identification of a causative antigen, time relation between exposure and disease, mosaic attenuation on chest imaging, and poorly formed non-necrotizing granulomas on pathology. In clinical scenarios, the diagnostic confidence of experts in cHP was heightened by the presence of these diagnostic items.ConclusionThis consensus-based approach for the diagnosis of cHP represents a first step towards the development of international guidelines for the diagnosis of cHP.

Published
2018

20. Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

Author

Raghu, Ganesh, Hamblin, Mark J., Brown, A. Whitney, Golden, Jeffrey A., Ho, Lawrence A., Wijsenbeek, Marlies S., Vasakova, Martina, Pesci, Alberto, Antin-Ozerkis, Danielle E., Meyer, Keith C., Kreuter, Michael, Burgess, Tracy, Kamath, Nikhil, Donaldson, Francis, and Richeldi, Luca

Published
2022
Full Text
View/download PDF

28. The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases:a systematic evidence synthesis

Author

Green, Rhiannon, Baldwin, Michael, Pooley, Nick, Misso, Kate, Mölken, Maureen PMH Rutten van, Patel, Nina, Wijsenbeek, Marlies S., Green, Rhiannon, Baldwin, Michael, Pooley, Nick, Misso, Kate, Mölken, Maureen PMH Rutten van, Patel, Nina, and Wijsenbeek, Marlies S.

Abstract

Background: Cough remains a persistent symptom in patients with idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). To inform future research, treatment and care models, we conducted the first systematic synthesis of evidence on its associated burden. Methods: A literature search was performed for articles published between January 2010 and October 2023 using databases including Embase, MEDLINE and the Cochrane Library. Studies in patients with IPF and other ILDs reporting cough-related measures were eligible for inclusion. Included studies were categorised based on the types of ILD they examined and their design. Study details, patient characteristics and outcomes were extracted, and the risk of bias was assessed. A narrative synthesis approach was employed to interpret the findings. Results: Sixty-one studies were included: 33 in IPF, 18 in mixed-ILDs, six in connective tissue disease-associated-ILDs and four in sarcoidosis. Across the studies, a range of tools to assess cough and its impact were used. The most frequently used measures of cough were cough severity visual analogue scale (VAS) and objective cough counts, whereas the most frequently used health-related quality of life (HRQoL)/impact measures were the St. George’s Respiratory Questionnaire (SGRQ) and Leicester Cough Questionnaire (LCQ). In IPF, studies consistently reported correlations between various cough and HRQoL measures, including between cough VAS scores and objective cough counts, LCQ scores and SGRQ scores. Similar correlations were observed in studies in other ILDs, but data were more limited. Qualitative studies in both IPF and other ILDs consistently highlighted the significant cough-related burden experienced by patients, including disruption of daily activities, fatigue and social embarrassment. Although there were no studies specifically investigating the economic burden of cough, one study in patie

Published
2024

29. ERS International Congress 2023: highlights from the Interstitial Lung Diseases Assembly

Author

Longziekten, Fabbri, Laura, Guiot, Julien, Vermant, Marie, Miądlikowska, Ewa, Estrella, Deborah, Wijsenbeek, Marlies S, Wuyts, Wim, Bargagli, Elena, Froidure, Antoine, Spagnolo, Paolo, Veltkamp, Marcel, Molina-Molina, Maria, McCarthy, Cormac, Antoniou, Katerina, Kreuter, Michael, Moor, Catharina C, Longziekten, Fabbri, Laura, Guiot, Julien, Vermant, Marie, Miądlikowska, Ewa, Estrella, Deborah, Wijsenbeek, Marlies S, Wuyts, Wim, Bargagli, Elena, Froidure, Antoine, Spagnolo, Paolo, Veltkamp, Marcel, Molina-Molina, Maria, McCarthy, Cormac, Antoniou, Katerina, Kreuter, Michael, and Moor, Catharina C

Published
2024

30. ERS International Congress 2023:highlights from the Interstitial Lung Diseases Assembly

Author

Fabbri, Laura, Guiot, Julien, Vermant, Marie, Miądlikowska, Ewa, Estrella, Deborah, Wijsenbeek, Marlies S., Wuyts, Wim, Bargagli, Elena, Froidure, Antoine, Spagnolo, Paolo, Veltkamp, Marcel, Molina-Molina, Maria, McCarthy, Cormac, Antoniou, Katerina, Kreuter, Michael, Moor, Catharina C., Fabbri, Laura, Guiot, Julien, Vermant, Marie, Miądlikowska, Ewa, Estrella, Deborah, Wijsenbeek, Marlies S., Wuyts, Wim, Bargagli, Elena, Froidure, Antoine, Spagnolo, Paolo, Veltkamp, Marcel, Molina-Molina, Maria, McCarthy, Cormac, Antoniou, Katerina, Kreuter, Michael, and Moor, Catharina C.

Abstract

This article summarises a selection of scientific highlights in the field of interstitial lung diseases (ILDs) presented at the International Congress of the European Respiratory Society in 2023. Translational and clinical studies focused on the whole spectrum of ILDs, from (ultra)rare ILDs to sarcoidosis, ILDs associated with connective tissue disease and idiopathic pulmonary fibrosis. The main topics of the 2023 Congress presentations were improving the diagnostic process of ILDs, better prediction of disease course and investigation of novel treatment options.

Published
2024

33. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study

Author

Raghu, Ganesh, van den Blink, Bernt, Hamblin, Mark J, Brown, A Whitney, Golden, Jeffrey A, Ho, Lawrence A, Wijsenbeek, Marlies S, Vasakova, Martina, Pesci, Alberto, Antin-Ozerkis, Danielle E, Meyer, Keith C, Kreuter, Michael, Moran, Donna, Santin-Janin, Hugues, Aubin, Francois, Mulder, Geert-Jan, Gupta, Renu, and Richeldi, Luca

Published
2019
Full Text
View/download PDF

35. Detection of Drug-induced Interstitial Lung Disease Caused by Cancer Treatment Using Electronic Nose Exhaled Breath Analysis.

Author

van der Sar, Iris G., Wijsenbeek, Marlies S., Dumoulin, Daphne W., Jager, Agnes, van der Veldt, Astrid A. M., Rossius, Mariska J. P., Dingemans, Anne-Marie C., and Moor, Catharina C.

Subjects
INTERSTITIAL lung diseases, LUNGS, ELECTRONIC noses, DRUG side effects, CANCER treatment, ETIOLOGY of cancer
Abstract

The article examines the rising concern of Drug-induced Interstitial Lung Disease (DIILD) in cancer treatments, emphasizing the urgent need for a noninvasive diagnostic tool. Topics discussed include DIILD incidence rates, challenges in diagnosis, and the potential of electronic nose technology to differentiate patients with DIILD from those without.

Published
2024
Full Text
View/download PDF

36. Increased proportions of circulating PD-1+ CD4+ memory T cells and PD-1+ regulatory T cells associate with good response to prednisone in pulmonary sarcoidosis.

Author

Miedema, Jelle R., de Jong, Lieke J., Kahlmann, Vivienne, Bergen, Ingrid M., Broos, Caroline E., Wijsenbeek, Marlies S., Hendriks, Rudi W., and Corneth, Odilia B. J.

Subjects
REGULATORY T cells, IMMUNOLOGIC memory, SARCOIDOSIS, T cells, VITAL capacity (Respiration)
Abstract

Background: The treatment response to corticosteroids in patients with sarcoidosis is highly variable. CD4+ T cells are central in sarcoid pathogenesis and their phenotype in peripheral blood (PB) associates with disease course. We hypothesized that the phenotype of circulating T cells in patients with sarcoidosis may correlate with the response to prednisone treatment. Therefore, we aimed to correlate frequencies and phenotypes of circulating T cells at baseline with the pulmonary function response at 3 and 12 months during prednisone treatment in patients with pulmonary sarcoidosis. Methods: We used multi-color flow cytometry to quantify activation marker expression on PB T cell populations in 22 treatment-naïve patients and 21 healthy controls (HCs). Pulmonary function tests at baseline, 3 and 12 months were used to measure treatment effect. Results: Patients with sarcoidosis showed an absolute forced vital capacity (FVC) increase of 14.2% predicted (± 10.6, p < 0.0001) between baseline and 3 months. Good response to prednisone (defined as absolute FVC increase of ≥ 10% predicted) was observed in 12 patients. CD4+ memory T cells and regulatory T cells from patients with sarcoidosis displayed an aberrant phenotype at baseline, compared to HCs. Good responders at 3 months had significantly increased baseline proportions of PD-1+CD4+ memory T cells and PD-1+ regulatory T cells, compared to poor responders and HCs. Moreover, decreased fractions of CD25+ cells and increased fractions of PD-1+ cells within the CD4+ memory T cell population correlated with ≥ 10% FVC increase at 12 months. During treatment, the aberrantly activated phenotype of memory and regulatory T cells reversed. Conclusions: Increased proportions of circulating PD-1+CD4+ memory T cells and PD-1+ regulatory T cells and decreased proportions of CD25+CD4+ memory T cells associate with good FVC response to prednisone in pulmonary sarcoidosis, representing promising new blood biomarkers for prednisone efficacy. Trial registration: NL44805.078.13 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

Author

Maher, Toby M, primary, Assassi, Shervin, additional, Azuma, Arata, additional, Cottin, Vincent, additional, Hoffmann-Vold, Anna-Maria, additional, Kreuter, Michael, additional, Oldham, Justin M, additional, Richeldi, Luca, additional, Valenzuela, Claudia, additional, Wijsenbeek, Marlies S, additional, Coeck, Carl, additional, Schlecker, Christina, additional, Voss, Florian, additional, Wachtlin, Daniel, additional, and Martinez, Fernando J, additional

Published
2023
Full Text
View/download PDF

47. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)

Author

Richeldi, Luca, primary, Azuma, Arata, additional, Cottin, Vincent, additional, Kreuter, Michael, additional, Maher, Toby M, additional, Martinez, Fernando J, additional, Oldham, Justin M, additional, Valenzuela, Claudia, additional, Gordat, Maud, additional, Liu, Yi, additional, Stowasser, Susanne, additional, Zoz, Donald F, additional, and Wijsenbeek, Marlies S, additional

Published
2023
Full Text
View/download PDF

49. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Author

Albera, Carlo, Antoniou, Katerina M., Altinisik, Goksel, Bendstrup, Elisabeth, Bondue, Benjamin, Borie, Raphael, Brown, Kevin K., Camus, Philippe, Castillo, Diego, Collard, Harold R., Cottin, Vincent, Crimi, Nunzio, Ferrara, Giovanni, Fischer, Aryeh, Gauldie, Jack, Geiser, Thomas, Guenther, Andreas, Hambly, Nathan, Hansell, David M., Harari, Sergio, Jones, Mark G., Keane, Michael, Ley, Brett, Maher, Toby M., Molina-Molina, Maria, Palmucci, Stefano, Poletti, Venerino, Prasse, Antje, Rottoli, Paola, Spagnolo, Paolo, Sterclova, Martina, Torrisi, Sebastiano, Tsitoura, Eliza, Vasakova, Martina, Walsh, Simon L., Wijsenbeek, Marlies S., Wuyts, Wim A., Johannson, Kerri A, Strâmbu, Irina, Ravaglia, Claudia, Grutters, Jan C, Valenzuela, Claudia, Mogulkoc, Nesrin, Luppi, Fabrizio, Richeldi, Luca, Wells, Athol U, Vancheri, Carlo, and Kreuter, Michael

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results